MARKET

SRZN

SRZN

Surrozen Inc
NASDAQ
17.84
-1.16
-6.11%
After Hours: 18.22 +0.38 +2.13% 19:30 09/14 EDT
OPEN
19.03
PREV CLOSE
19.00
HIGH
19.29
LOW
17.61
VOLUME
198.20K
TURNOVER
--
52 WEEK HIGH
35.00
52 WEEK LOW
11.25
MARKET CAP
209.68M
P/E (TTM)
-0.4985
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SRZN last week (0907-0911)?
Weekly Report · 20h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)
TipRanks · 5d ago
Surrozen submits investigational new drug application for SZN-8141
TipRanks · 6d ago
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Benzinga · 6d ago
Weekly Report: what happened at SRZN last week (0831-0904)?
Weekly Report · 09/07 09:30
Weekly Report: what happened at SRZN last week (0824-0828)?
Weekly Report · 08/31 09:33
Weekly Report: what happened at SRZN last week (0817-0821)?
Weekly Report · 08/24 09:33
Surrozen initiated with an Outperform at William Blair
TipRanks · 08/20 10:05
More
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Webull offers Surrozen Inc stock information, including NASDAQ: SRZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRZN stock methods without spending real money on the virtual paper trading platform.